SequelSEC

Rapport Therapeutics, Inc. RAPP

Pharmaceutical Preparations · CIK 0002012593 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$125.10M
Fiscal year ended 2025-12-31
Free cash flow
-$88.09M
Fiscal year ended 2025-12-31

Rapport Therapeutics, Inc. (RAPP) reported net income of -$111.48M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from Rapport Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Rapport Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
RevenueUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$125.10M-$83.06M-$36.18M
Net income-$111.48M-$78.31M-$34.79M
Research & development$94.79M$60.94M$28.00M
Weighted-average diluted sharesshares 38.93Mshares 20.74Mshares 1.51M
Pretax incomeUnavailable-$78.31M-$34.78M
Income tax expense$0$0$10.00K
Diluted EPS$-2.86$-3.78$-23.10
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$30.31M$22.12M$8.18M
Selling & marketingUnavailableUnavailableUnavailable

Balance

Rapport Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Cash & equivalents$52.64M$56.80M$70.17M
Total assets$512.43M$314.93M$155.42M
Current assets$498.56M$309.80M$150.87M
Total liabilities$27.78M$9.51M$14.48M
Current liabilities$19.05M$8.77M$8.80M
Total equity incl. NCI$484.65M$305.43M-$25.63M
Temporary (mezzanine) equityUnavailableUnavailable$166.58M
InventoryUnavailableUnavailableUnavailable
Accounts receivable$0UnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$4.19M$1.95M$2.50M

Cash flow

Rapport Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Operating cash flow-$87.47M-$64.83M-$27.18M
Capital expenditures$616.00K$2.40M$1.64M
Investing cash flow-$187.47M-$170.14M-$78.86M
Financing cash flow$270.79M$221.62M$145.14M
Net change in cash-$4.16M-$13.34M$39.10M
Stock-based compensation$18.86M$10.24M$3.52M
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortization$1.02M$839.00K$112.00K

Derived

Rapport Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Free cash flow-$88.09M-$67.23M-$28.82M
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio26.17x35.34x17.14x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RAPP in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-10View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.